See more : OceanTech Acquisitions I Corp. (OTECW) Income Statement Analysis – Financial Results
Complete financial analysis of NanoViricides, Inc. (NNVC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoViricides, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Frontier Lithium Inc. (FL.V) Income Statement Analysis – Financial Results
- V. B. Industries Limited (VBIND.BO) Income Statement Analysis – Financial Results
- Polestar Automotive Holding UK PLC (PSNY) Income Statement Analysis – Financial Results
- Anoto Group AB (publ) (AOTOF) Income Statement Analysis – Financial Results
- Agios Pharmaceuticals, Inc. (0HB0.L) Income Statement Analysis – Financial Results
NanoViricides, Inc. (NNVC)
About NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K | -695.91K | -680.06K | -662.95K | -659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.44M | 6.39M | 5.78M | 6.11M | 4.70M | 5.92M | 4.83M | 5.53M | 5.03M | 3.66M | 5.13M | 4.29M | 4.27M | 4.16M | 3.20M | 1.73M | 839.24K | 731.81K | 899.89K | 30.77K |
| General & Administrative | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 1.70M | 35.23K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -142.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Cost & Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Interest Income | 221.97K | 355.83K | 11.86K | 9.35K | 17.08K | 55.50K | 100.43K | 60.96K | 62.64K | 160.86K | 171.00K | 55.59K | 46.79K | 14.34K | 0.00 | 31.93K | 0.00 | 54.51K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 938.00 | 5.12K | 85.41K | 93.67K | 0.00 | 544.49K | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 90.56K | 0.00 | 0.00 |
| Depreciation & Amortization | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 302.74K | 212.01K | 219.65K | 219.65K | 527.74K | 90.29K | 12.29K | 13.47K | 36.30K | 44.56K | 0.00 |
| EBITDA | -7.76M | -7.84M | -7.38M | -8.03M | -7.30M | -7.96M | -8.59M | -8.94M | -8.20M | -6.76M | -8.46M | -7.56M | -5.99M | -5.95M | -4.65M | -2.83M | -2.73M | -3.03M | -2.55M | -66.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M | -8.66M | -9.33M | -9.60M | -8.86M | -7.06M | -8.67M | -6.59M | -6.08M | -6.43M | -4.94M | -2.82M | -2.79M | -3.08M | -2.60M | -66.01K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 221.97K | 354.90K | 6.74K | -78.08K | -5.45M | 235.24K | 761.71K | -703.77K | -1.87M | 4.86M | -4.93M | -2.29M | -125.46K | -47.71K | 358.27K | -26.20K | 53.70K | -36.05K | -688.58K | 0.00 |
| Income Before Tax | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2,787.80B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 355.83K | -6.74K | 85.41K | -49.00K | -179.75K | 1.31M | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 125.46K | 47.71K | -195.74K | 31.93B | -53.70K | 36.05K | 688.58K | 66.01K |
| Net Income | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M | -8.24M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66.01K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.78 | -5.51 | -3.87 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| EPS Diluted | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.74 | -5.51 | -3.73 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| Weighted Avg Shares Out | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.83M | 2.56M | 2.29M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
| Weighted Avg Shares Out (Dil) | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.96M | 2.56M | 2.38M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
NanoViricides spotlights lead drug candidate's potential as COVID therapy
NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies of NV-387 have shown it can be “highly effective” in treating COVID infections.
NanoViricides discusses lead program and next steps
NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown activity against various respiratory viral infections in animal models.
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory...
NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin first Phase II trials. NV-387 has successfully completed Phase I clinical...
NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed three approved flu medications—Tamiflu (Oseltamivir), Rapivab (Peramivir), and Xofluza (Baloxavir)—in treating severe lung...
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu...
NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infection mouse model. Investors welcomed the news, sending shares of NanoViricides (NYSE-A:NNVC) up 11% to US$1.82 in...
NanoViricides antiviral candidate 'may be first effective oral nanomedicine'
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way. NV-387 demonstrated an ideal flat blood concentration profile for extended periods upon oral...
NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could enable infrequent dosing. The company said when administered intravenously in a non-human primate animal model, NV-387 demonstrated...
NanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicines
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and influenzas. CEO Dr Anil Diwan told investors that, if approved, NV-387 could be “as revolutionary an...
Source: https://incomestatements.info
Category: Stock Reports